The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function.

The matrix metalloproteinases (MMPs) comprise a family of at least 20 proteolytic enzymes that play an essential role in tissue remodeling. MMP1 (interstitial collagenase), MMP9 (gelatinase B) and MMP12 (macrophage elastase) are thought to be important in the development of emphysema. A number of naturally occurring polymorphisms of human MMP gene promoters have been identified and found to alter transcriptional activity. Additionally, we detected a novel polymorphism in the MMP12 coding region (Asn357Ser). The aim of this study was to investigate the role of MMP polymorphisms in the development of chronic obstructive lung disease. We determined the prevalence of these polymorphisms in 590 continuing smokers chosen from the National Heart Lung and Blood Institute, Lung Health Study for having the fastest (n = 284) and slowest (n = 306) 5 year rate of decline of lung function. Of the five polymorphisms, only G-1607GG was associated with a rate of decline in lung function. The -1607GG allele was associated with a fast rate of decline (P = 0.02) [corrected]. However, haplotypes consisting of alleles from the MMP1 G-1607GG and MMP12 Asn357Ser polymorphisms were associated with rate of decline of lung function (P = 0.0007). These data suggest that polymorphisms in the MMP1 and MMP12 genes, but not MMP9, are either causative factors in smoking-related lung injury or are in linkage disequilibrium with causative polymorphisms.

[1]  J. D’Armiento,et al.  Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. , 2001, American journal of respiratory and critical care medicine.

[2]  I. Day,et al.  Invasiveness of cutaneous malignant melanoma is influenced by matrix metalloproteinase 1 gene polymorphism. , 2001, Cancer research.

[3]  J. Foidart,et al.  Matrix metalloproteinases and TIMP‐1 production by peripheral blood granulocytes from COPD patients and asthmatics , 2001, Allergy.

[4]  J. Foidart,et al.  MMP-2- and MMP-9-Linked Gelatinolytic Activity in the Sputum from Patients with Asthma and Chronic Obstructive Pulmonary Disease , 2000, International Archives of Allergy and Immunology.

[5]  A. Vasku,et al.  Functional polymorphism in the gelatinase B gene and asthma , 2000, Allergy.

[6]  Yusuke Nakamura,et al.  A Single Nucleotide Polymorphism in the Matrix Metalloproteinase‐1 Promoter in Endometrial Carcinomas , 2000, Japanese journal of cancer research : Gann.

[7]  T. Olsson,et al.  Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis , 2000, Journal of Neuroimmunology.

[8]  A M Zeiher,et al.  Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. , 2000, Circulation research.

[9]  M. Gaxiola,et al.  Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. , 2000, Chest.

[10]  H Yonas,et al.  Functional polymorphism in the matrix metalloproteinase-9 promoter as a potential risk factor for intracranial aneurysm. , 1999, Stroke.

[11]  Y. Nakamura,et al.  Correlation between expression of the matrix metalloproteinase-1 gene in ovarian cancers and an insertion/deletion polymorphism in its promoter region. , 1999, Cancer research.

[12]  Y. Sasaguri,et al.  Shortened microsatellite d(CA)21 sequence down‐regulates promoter activity of matrix metalloproteinase 9 gene , 1999, FEBS letters.

[13]  A. Evans,et al.  Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. , 1999, Circulation.

[14]  D. Hartmann,et al.  Contribution of 92 kDa gelatinase/type IV collagenase in bronchial inflammation during status asthmaticus. , 1999, American journal of respiratory and critical care medicine.

[15]  K. Shirato,et al.  Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. , 1999, Journal of immunology.

[16]  P. Cohen,et al.  Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle. , 1999, American journal of respiratory cell and molecular biology.

[17]  L. Boulet,et al.  Serum matrix metalloproteinase-9:Tissue inhibitor of metalloproteinase-1 ratio correlates with steroid responsiveness in moderate to severe asthma. , 1999, American journal of respiratory and critical care medicine.

[18]  J. Gusella,et al.  A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. , 1998, Cancer research.

[19]  J. Bousquet,et al.  Sputum metalloproteinase-9/tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. , 1998, American journal of respiratory and critical care medicine.

[20]  Y. Konttinen,et al.  Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[21]  D. Levy,et al.  Segregation analysis of pulmonary function among families in the Framingham Study. , 1998, American journal of respiratory and critical care medicine.

[22]  S. Shapiro,et al.  Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. , 1997, Science.

[23]  L. O’Driscoll,et al.  Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. , 1997, American journal of respiratory and critical care medicine.

[24]  C. O'connor,et al.  Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. , 1997, Thorax.

[25]  P. Sham.  Statistics in human genetics , 1997 .

[26]  C. López-Otín,et al.  Fine physical mapping of the human matrix metalloproteinase genes clustered on chromosome 11q22.3. , 1996, Genomics.

[27]  J. Epplen,et al.  Genomic simple repetitive DNAs are targets for differential binding of nuclear proteins , 1996, FEBS letters.

[28]  S. Weiss,et al.  A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary-function decline: the Normative Aging Study. , 1995, American journal of respiratory and critical care medicine.

[29]  B. Rosner,et al.  Airway hyperresponsiveness to histamine associated with accelerated decline in FEV1. , 1995, American journal of respiratory and critical care medicine.

[30]  S. Holgate,et al.  The influence of increased bronchial responsiveness, atopy, and serum IgE on decline in FEV1. A longitudinal study in the elderly. , 1995, American journal of respiratory and critical care medicine.

[31]  W. Bailey,et al.  Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. , 1993, Controlled clinical trials.

[32]  Y. Okada,et al.  Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema , 1992, Cell.

[33]  L. Chow,et al.  Structure of the human type IV collagenase gene. , 1990, The Journal of biological chemistry.

[34]  M. Ashburner.  A Laboratory manual , 1989 .

[35]  F. Speizer,et al.  The natural history of forced expiratory volumes. Effect of cigarette smoking and respiratory symptoms. , 1988, The American review of respiratory disease.

[36]  F. Speizer,et al.  Assessment of genetic and nongenetic influences on pulmonary function. A twin study. , 2015, The American review of respiratory disease.

[37]  Y. Okada,et al.  Matrix metalloproteinases 1, 2, and 3 from rheumatoid synovial cells are sufficient to destroy joints. , 1987, The Journal of rheumatology.

[38]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[39]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[40]  O. Hill.  A Twin Study , 1968, British Journal of Psychiatry.

[41]  C. Laurell,et al.  The Electrophoretic α;1-Globulin Pattern of Serum in α;1-Antitrypsin Deficiency , 1963 .